Market capitalization | $4.98b |
Enterprise Value | $4.42b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 9.13 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-298.51m |
Free Cash Flow (TTM) Free Cash Flow | $-243.55m |
Cash position | $560.01m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
15 Analysts have issued a Immunovant Inc forecast:
15 Analysts have issued a Immunovant Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.55 -0.55 |
59%
59%
|
|
EBITDA | -298 -298 |
22%
22%
|
EBIT (Operating Income) EBIT | -299 -299 |
21%
21%
|
Net Profit | -273 -273 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
Head office | United States |
CEO | Peter Salzmann |
Employees | 207 |
Founded | 2018 |
Website | www.immunovant.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.